Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer

BACKGROUND: A minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector function of activated T and NK cells may lead to reduced tumor cell death, even when these activated effector cells are released f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Hurkmans, Daan P., Basak, Edwin A., Schepers, Nina, Oomen-De Hoop, Esther, Van der Leest, Cor H., El Bouazzaoui, Samira, Bins, Sander, Koolen, Stijn L. W., Sleijfer, Stefan, Van der Veldt, Astrid A. M., Debets, Reno, Van Schaik, Ron H. N., Aerts, Joachim G. J. V., Mathijssen, Ron H. J.
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7254154/
https://ncbi.nlm.nih.gov/pubmed/32461348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000586
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados